• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Canadian university set for Phase 2 human trials of inhaled COVID-19 vaccine

January 20, 2023 By Sean Whooley

McMaster University COVID-19 inhaled vaccine
[Image courtesy of Georgia Kirkos, McMaster University]
Researchers at McMaster University in Canada announced that they received $8.2 million from the Canadian Institutes of Health Research (CIHR).

Fiona Smaill picked up $8.2 million to advance an inhaled COVID-19 vaccine through to Phase 2 human trials. The trials will evaluate the safety and immunogenicity of the next-generation vaccine delivered by inhaled aerosol. Her work comes as part of Canada’s Global Nexus for Pandemics and Biological Threats at McMaster.

Researchers expect the study to begin in the coming months and involve up to 500 participants. These participants received at least three doses of an mRNA vaccine. It includes people who represent older populations, or those with health conditions and may have prior history of COVID infection.

According to the school, it has the potential to lead to better protection against COVID strains. That includes Omicron variants.

“If we can show the new inhaled vaccine is safe and effective, as we anticipate, the impact will be significant for human health, medical costs and better quality of life,” said Smaill, professor emeritus in the department of Pathology and Molecular Medicine.

Smaill leads the trials with Mathew Miller, Zhou Xing, Brian Lichty, Mark Loeb and Imran Satia. Miller serves as scientific director of the Michael G. DeGroote Institute for Infectious Disease Research. Xing is a professor of medicine and Lichty is an associate professor of medicine. Loeb serves as a professor of pathology and molecular medicine and Canada Research Chair in Infectious Diseases Research. Imran Satia is an assistant professor of respirology.

“Our researchers continue to produce evidence-based research to advance the health and well-being of Canadians and citizens around the world and have helped McMaster and Canada earn a global reputation as leaders in clinical trials,” said Karen Mossman, McMaster’s VP of research.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Research & Development, Respiratory Tagged With: coronavirus, COVID-19, McMaster University

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS